FDA announces a new priority review program in bid to further administration goals

WASHINGTON — The Food and Drug Administration is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions align with the agency’s national health priorities. 

Those priorities include addressing unmet public health needs or health crises, beefing up domestic production of drugs, and delivering more innovative cures, according to a press release from the health department. 

The Tuesday announcement lines up with the Trump administration’s broader effort to achieve its health care priorities without issuing regulations. Among other steps, it is trying to push companies to lower drug prices and build more factories in the U.S. by threatening dramatic tariffs and tying prices to those paid overseas.